CHARM predicts who may need extra care after transplant. Read about this CIBMTR study to learn more: cibmtr.org/Patient-Summ...

People with sickle cell trait can safely donate bone marrow. Read about this CIBMTR study to learn more: cibmtr.org/Patient-Summ...

Graphs can help patients and doctors see healing over time. Read about this CIBMTR study to learn more: cibmtr.org/Patient-Summ...

Some children with SCID might not need chemotherapy before transplant or GVHD medicines after transplant. Read about this CIBMTR study to learn more: cibmtr.org/Patient-Summ...

Don't miss this! Abstracts from #Tandem26 are now available to view online. Explore the full collection here: www.astctjournal.org/issue/S2666-...

A special congratulations to Dr. Stella Davies, our #Tandem26 Mortimer M. Bortin lecturer! It is our pleasure to now hear, “Waiting until Evening to See How Splendid the Day Has Been: Aging and Transplant at the Extremes of the Lifespan” this evening!

Congratulations to CIBMTR Distinguished Service Award recipient, Dr. Parvez Ahmed at #Tandem26

Dr. Rachel Cusatis, CIBMTR Senior Scientific Director, is now presenting oral abstract, “Mismatch Doesn’t Mean Misfortune: Quality of Life after HCT in the ACCESS Trial,” at #Tandem26.

Have you had a chance to visit the #Tandem26 exhibit hall? Make sure to stop by the Tandem Meetings Hub to visit with CIBMTR staff! Open today until 3 p.m. and 9 a.m.-12 p.m. tomorrow!

A Wednesday session at #Tandem26 took a closer look at where gene therapy stands today—what’s working, what’s holding it back, and what’s coming next. Check out the full recap in Tandem Meeting News: www.tandemmeetingsnews.com/experts-disc...

What's next for HCT and cellular therapies? The #Tandem26 opening-day plenary examined progress from breakthrough to bedside — looking toward equitable access and improved care. Read more in Tandem Meeting News: www.tandemmeetingsnews.com/joint-plenar...

#tandem26 #bmtsm Spellman: @cibmtr.bsky.social study shows equivalent GRFS w MRD and MUD but alternative donors far slightly worse. Avoid DPB1np mm in MUD, but this mm type *may* be protective in haplo.

#tandem26 #bmtsm Spellman: matched sibs remain preferred donor when available, though some are starting to use age cap ~40-50, though this remains uncertain.

#tandem26 #bmtsm Spellman: with expanded use of MMUD, essentially everyone can find a donor.

#tandem26 #bmtsm Spellman: updated guidelines for donor selection from @cibmtr.bsky.social. Partially driven by massive expanded use of PTCy.

#tandem26 #bmtsm Auletta: world-wide unrelated and haplodentical donors are driving growth in alloHCT. PTCy has rapidly become predominant GVHD ppx across donor types.

🔬 NMDP and CIBMTR are presenting new findings from the ACCESS study at #Tandem2026. These new findings highlight important dimensions of transplant outcomes and patient experience following mismatched unrelated donor (MMUD) transplantation 👉 go.nmdp.org/Tandem2026

Attending #Tandem26 and looking for session locations in the Salt Palace Convention Center? Here are few helpful maps! @astct.bsky.social

Dr. Miguel-Angel Perales (@drmiguelperales.bsky.social) concludes the CIBMTR Concurrent Session with “Use of CIBMTR One Year Survival Calculator for Retrospective Analysis” at #Tandem26 this morning!

Drs. Doug Rizzo and Navneet Majhail (@bldcancerdoc.bsky.social) collaborate to chair the outstanding “Concurrent: Beyond the Report Card – Advancing Research and Quality through Center Specific Outcomes Reporting [CIBMTR]” this morning at #Tandem26

It's not too late to add the NMDP/CIBMTR community to your #Tandem2026 agenda! Check out these notable presentations from the ACCESS Trial ⬇️

CIBMTR’s February 2026 Newsletter is out now! Catch new Perspectives, Working Committee updates, the latest Page Scholars, news from BMT CTN and ACT Corner, and a look ahead to the 2026 Tandem Meetings. Read here: cibmtr.org/CIBMTR/About...

CIBMTR's 2025 Annual Report is now available to view on our website. Thank you for helping us make 2025 another successful year! cibmtr.org/Files/Admini...

Experts say a 24-hour caregiver is not necessary for people who receive blood or marrow transplants. Read about this CIBMTR study to learn more: cibmtr.org/Patient-Summ...

HOUSING FRAUD ALERT: Attending #Tandem26? Book your 2026 Tandem Meetings housing only through onPeak using the info emailed to you. Ignore third-party offers and never share personal details. Questions? Contact [email protected].

Final call! Tomorrow is the last day to submit late-breaking or federal investigator abstracts for #Tandem26. If you have new scientific findings or are a federal investigator, submit your abstract tomorrow, Dec. 23: www.tandemmeetings.com/Abstracts/Ab...

The Tandem Meetings is now accepting late-breaking abstracts and abstracts from federal investigators! Eligible abstracts will be selected for oral presentation. Submit your HCT, cell and gene therapy research findings by Dec. 23: ow.ly/MwiC50XHtyJ@...

HOUSING FRAUD ALERT: Attending #Tandem26? Book your 2026 Tandem Meetings housing only through onPeak using the info emailed to you. Ignore third-party offers and never share personal details. Questions? Contact [email protected].

Thank you to everyone who visited CIBMTR’s booth and attended oral and poster abstract sessions during #ASH25! We look forward to seeing you Feb. 4-7, 2026, for #Tandem26!

Attending #ASH25 this weekend? If so, make sure to stop by the CIBMTR booth (#782) in the exhibit hall – for a special opportunity to save on your #Tandem26 registration! You can also view a list of all CIBMTR abstracts, here: cibmtr.org/Files/Meetin...

People with multiple myeloma and their doctors say that there are 6 main obstacles to getting a transplant. Read about this CIBMTR study to learn more:

Have you seen our newly redesigned Study Summaries webpage?! These summaries are written specifically for patients and they are now easier to navigate! You can search by keyword and filter by category to quickly find exactly what you need. Try out the new features today! www.cibmtr.org/summaries

Don’t miss your chance to secure the lowest registration rates for #Tandem26, Feb 4–7, 2026 in Salt Lake City. Experience four days to learn, collaborate & advance expertise in HCT, cellular & gene therapy. Register before Dec 6: www.tandemmeetings.com/Registration...

Elevate your expertise in transplantation, cell, and gene therapy from discovery to delivery at #Tandem26. Join us in February 2026 in Salt Lake City to explore breakthroughs, connect with leaders, and move the field forward. www.youtube.com/watch?v=vqnd...

CIBMTR's November Newsletter is now available! Read a message from our Advisory Committee Chair, about our new Immunobiology Working Committee Co-Scientific Director, a leadership transition for CIBMTR ACT, our new Page Scholars, and much more! Read online: cibmtr.org/CIBMTR/About...

Senior Scientific Director of Patient-Centered Research and Survivorship, CIBMTR MCW, Dr. Rachel Cusatis, is now presenting at the CIBMTR Symposium at x.com/ISOQOL

Dive into the latest advancements in #HCT research at #Tandem26! Register today to reserve your spot in Salt Lake City, Feb. 4-7, 2026! View the scientific program: tandem.virtual-meeting.org/programme

CIBMTR’s patient-reported outcomes team presenting at the CIBMTR-sponsored symposium during this week’s ISOQOL conference!

CIBMTR is proud to be attending and presenting at the 2025 ISOQOL Conference this week! Stay tuned for more information! Learn more, here: cibmtr.org/CIBMTR/About...

Getting #BMT after an organ transplant may be risky, according to a recent CIBMTR study. Read more about the results of this study: cibmtr.org/Files/Patien...

Registration for #Tandem26 is officially open! Don’t miss the opportunity to join us in Salt Lake City in February 2026. Reserve your spot today! Learn more and register today: www.tandemmeetings.com/.../Registra...

New Working Committee Co-Scientific Director: Rohtesh Mehta, MD, MPH, MS, to serve as co-Scientific Director of the Immunobiology Working Committee. Read more about this exciting announcement: cibmtr.org/CIBMTR/About...

It gives us great pleasure to announce that Amy Moskop, MD, MS, has been confirmed as the new co-Principal Investigator (PI) on U24-CA076518: A Data Resource for Blood and Marrow Transplants and Adoptive Cellular Therapy Research. Read more: cibmtr.org/CIBMTR/About...

CIBMTR and the MCW Division of Hematology and Oncology invite applications for a faculty position as a CIBMTR Scientific Director. Learn more about and apply for this important position: careers.peopleclick.com/careerscp/cl...

💡 Present your science on one of the biggest stages in hematopoietic cell transplantation, gene and cellular therapy. Submit an abstract by Oct. 9 and help shape the scientific program at the 2026 Tandem Meetings: ow.ly/wyrJ50WMqJY #Tandem26

For patients unlikely to have a fully matched donor, their team should quickly switch to searching for alternate (mismatched) donors. Read more about this BMT CTN study just published in the Journal of Clinical Oncology: cibmtr.org/Files/Patien...

Just over a month until ISOQOL 2025! A symposium will feature CIBMTR, highlighting the integration of PROs into clinical registries for HCT and cellular therapy, including HCT and CAR-T. Learn more: cibmtr.org/CIBMTR/About...

Abstract submission for #Tandem26 is now open! ASTCT and CIBMTR invite you to share your research with 5,000+ HCT, cell, and gene therapy colleagues in Salt Lake City, UT, February 4-7, 2026! Learn more and submit an abstract at www.tandemmeetings.com/Abstracts/Ab...

There is not much data about what happens to patients who don’t have a caregiver after transplant. But most doctors won’t provide #BMT to patients who don’t have a caregiver. Experts say that should change. Read more: cibmtr.org/Files/Patien...

According to a recent study, nearly 100% of people said that it’s very important that researchers ask patients directly about their quality of life. Read more: cibmtr.org/Files/Patien...